Pcdhb19 Inhibitors
Pcdhb19 inhibitors pertain to a class of chemical compounds that specifically target and inhibit the function of the protein encoded by the Pcdhb19 gene, which is a member of the protocadherin beta gene cluster. These inhibitors are designed based on the unique molecular interactions and the structural biology of the Pcdhb19 protein. The protocadherin family is characterized by their role in cell-cell adhesion, where they contribute to the specificity of neuronal connections and play a role in the complex signaling pathways that govern cellular processes. The Pcdhb19 gene, in particular, encodes a protein that is a part of the cadherin superfamily, a group of proteins that mediate calcium-dependent intercellular adhesion and are crucial in maintaining the structure and function of cells in various tissues.
Inhibitors of Pcdhb19 are synthesized through a meticulous process that involves understanding the binding domains and the conformational dynamics of the protein. They are typically small molecules that can interact with the active or allosteric sites of the Pcdhb19 protein, leading to a conformational change or steric hindrance that results in the downregulation of its activity. The specificity of these compounds is paramount to ensure minimal off-target effects, as the protocadherin family includes many homologous proteins with similar structures and functions. The development of Pcdhb19 inhibitors involves extensive research into the protein's structure, the mechanisms by which it contributes to cellular signaling, and the identification of potential binding pockets that can be exploited by the inhibitors. By focusing on these aspects, the inhibitors are crafted to achieve maximum efficacy in modulating the function of the Pcdhb19 protein without affecting other proteins in the protocadherin family or other unrelated cellular components.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators of the Akt signaling pathway. Inhibition of PI3K activity results in decreased Akt phosphorylation, thereby potentially reducing the downstream signaling that might regulate Pcdhb19 expression or activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that blocks the PI3K/Akt pathway. By decreasing Akt signaling, LY294002 may indirectly reduce the functional activity of Pcdhb19, if Pcdhb19 activity is modulated by the Akt pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin), which is part of mTOR signaling pathway important for cell growth and proliferation. Inhibition of mTOR could impact cellular processes that indirectly influence Pcdhb19 function or expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which acts upstream of ERK in the MAPK/ERK pathway. Inhibition of this pathway may affect cellular processes that are involved in the regulation of Pcdhb19 activity or expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also an inhibitor of MEK1/2, which can prevent the activation of the MAPK/ERK pathway. Through these actions, U0126 might indirectly influence the functional activity of Pcdhb19 by altering the cellular context in which Pcdhb19 operates. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinases), a part of the MAPK pathway. By inhibiting JNK, SP600125 could affect signaling pathways that modulate the activity or expression of Pcdhb19. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, another kinase in the MAPK pathway. This inhibition can lead to changes in signaling events that might be necessary for Pcdhb19 activity or stability. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV-939 inhibits Wnt signaling by stabilizing axin, which promotes the degradation of β-catenin. Although Pcdhb19 is not directly in the Wnt pathway, changes in cell signaling due to Wnt inhibition could indirectly impact Pcdhb19 function. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a γ-secretase inhibitor, which prevents the cleavage and activation of Notch receptors. Notch signaling can have numerous downstream effects, potentially influencing the expression or function of Pcdhb19 indirectly. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine is an inhibitor of the Hedgehog signaling pathway by targeting Smoothened. This inhibition could alter cellular processes and signaling pathways that indirectly affect Pcdhb19 activity or expression. | ||||||